Literature DB >> 31481749

Intestinal proteomic analysis of a novel non-human primate model of experimental colitis reveals signatures of mitochondrial and metabolic dysfunction.

Peter McQueen1,2, Kathleen Busman-Sahay3, Florian Rieder4,5, Laura Noël-Romas1,2, Stuart McCorrister6, Garrett Westmacott6, Jacob D Estes3,7, Adam Burgener8,9,10,11.   

Abstract

Animal models recapitulating features of chronic colitis, such as ulcerative colitis, Crohn's disease, or HIV infection, are critical to study disease pathogenesis and test novel therapeutics. In this study, we used a proteomics approach to explore the molecular intestinal response in two rhesus macaque (RM) animal models of experimentally induced colitis using dextran sulfate sodium (DSS) and simian immunodeficiency virus (SIV) infection. Proteomic analysis detected more than 2500 proteins in colonic tissue collected from 30 RMs. Differential protein expression analysis revealed a protein expression pattern in DSS-treated RMs resembling the proteome of human ulcerative colitis. In a group of 12 DSS-treated RMs compared to 6 with no treatment, decrease in expression of proteins related to mitochondrial energy metabolism, including fatty acid metabolism was noted, while innate immune activation pathways, including complement and coagulation proteins were upregulated. SIV infection of RMs resulted in increased innate immune responses related to viral defense. Proteomic signatures of barrier damage were apparent in both DSS treatment or SIV infection. These results demonstrate that DSS treatment in a non-human primate model resembles features of human ulcerative colitis, making this a promising tool to study important immunological mechanisms in inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31481749      PMCID: PMC7673647          DOI: 10.1038/s41385-019-0200-2

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  47 in total

Review 1.  Immunopathogenesis of IBD: current state of the art.

Authors:  Heitor S P de Souza; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-12-02       Impact factor: 46.802

Review 2.  NADPH oxidases and inflammatory bowel disease.

Authors:  Giang Lam; Vasso Apostolopoulos; Anthony Zulli; Kulmira Nurgali
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

Review 3.  Inflammatory bowel disease: clinical aspects and established and evolving therapies.

Authors:  Daniel C Baumgart; William J Sandborn
Journal:  Lancet       Date:  2007-05-12       Impact factor: 79.321

4.  Humoral immune system in inflammatory bowel disease: I. Complement levels.

Authors:  H J Hodgson; B J Potter; D P Jewell
Journal:  Gut       Date:  1977-09       Impact factor: 23.059

5.  Apoptosis of crypt epithelial cells in ulcerative colitis.

Authors:  M Iwamoto; T Koji; K Makiyama; N Kobayashi; P K Nakane
Journal:  J Pathol       Date:  1996-10       Impact factor: 7.996

6.  Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease.

Authors:  Anna Shkoda; Tanja Werner; Hannelore Daniel; Manuela Gunckel; Gerhard Rogler; Dirk Haller
Journal:  J Proteome Res       Date:  2007-03       Impact factor: 4.466

Review 7.  Treatment of inflammatory bowel disease: a review of medical therapy.

Authors:  Patricia L Kozuch; Stephen B Hanauer
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

8.  Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections.

Authors:  Jacob D Estes; Levelle D Harris; Nichole R Klatt; Brian Tabb; Stefania Pittaluga; Mirko Paiardini; G Robin Barclay; Jeremy Smedley; Rhonda Pung; Kenneth M Oliveira; Vanessa M Hirsch; Guido Silvestri; Daniel C Douek; Christopher J Miller; Ashley T Haase; Jeffrey Lifson; Jason M Brenchley
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

Review 9.  Murine models of inflammatory bowel disease (IBD): challenges of modeling human disease.

Authors:  Jason DeVoss; Lauri Diehl
Journal:  Toxicol Pathol       Date:  2013-11-13       Impact factor: 1.902

10.  Experimental colitis in SIV-uninfected rhesus macaques recapitulates important features of pathogenic SIV infection.

Authors:  Xing Pei Hao; Carissa M Lucero; Baris Turkbey; Marcelino L Bernardo; David R Morcock; Claire Deleage; Charles M Trubey; Jeremy Smedley; Nichole R Klatt; Luis D Giavedoni; Jan Kristoff; Amy Xu; Gregory Q Del Prete; Brandon F Keele; Srinivas S Rao; W Gregory Alvord; Peter L Choyke; Jeffrey D Lifson; Jason M Brenchley; Cristian Apetrei; Ivona Pandrea; Jacob D Estes
Journal:  Nat Commun       Date:  2015-08-18       Impact factor: 14.919

View more
  5 in total

1.  Ilex rotunda Thunb Protects Against Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice by Restoring the Intestinal Mucosal Barrier and Modulating the Oncostatin M/Oncostatin M Receptor Pathway.

Authors:  Yao Li; Xu Yang; Jia-Ni Yuan; Rui Lin; Yun-Yuan Tian; Yu-Xin Li; Yan Zhang; Xu-Fang Wang; Yan-Hua Xie; Si-Wang Wang; Xiao-Hui Zheng
Journal:  Front Pharmacol       Date:  2022-05-13       Impact factor: 5.988

2.  Mitigation of endemic GI-tract pathogen-mediated inflammation through development of multimodal treatment regimen and its impact on SIV acquisition in rhesus macaques.

Authors:  Rachele M Bochart; Kathleen Busman-Sahay; Stephen Bondoc; David W Morrow; Alexandra M Ortiz; Christine M Fennessey; Miranda B Fischer; Oriene Shiel; Tonya Swanson; Christine M Shriver-Munsch; Hugh B Crank; Kimberly M Armantrout; Aaron M Barber-Axthelm; Charlotte Langner; Cassandra R Moats; Caralyn S Labriola; Rhonda MacAllister; Michael K Axthelm; Jason M Brenchley; Brandon F Keele; Jacob D Estes; Scott G Hansen; Jeremy V Smedley
Journal:  PLoS Pathog       Date:  2021-05-10       Impact factor: 7.464

3.  Exploratory clinical characterization of experimentally-induced ulcerative colitis nonhuman primates.

Authors:  Nobuyuki Takahashi; Chinatsu Kitazawa; Yoshitaka Itani; Yuji Awaga; Aldric Hama; Ikuo Hayashi; Hiroyuki Takamatsu
Journal:  Heliyon       Date:  2020-01-09

4.  Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies.

Authors:  Hongyu Qiu; Xin-Yong Yuan; Teresa Cabral; Kathy Manguiat; Alyssia Robinson; Heidi Wood; Chris Grant; Peter McQueen; Garrett Westmacott; Daniel R Beniac; Lisa Lin; Michael Carpenter; Darwyn Kobasa; Tom Gräfenhan
Journal:  Antiviral Res       Date:  2021-11-08       Impact factor: 5.970

5.  Atractylenolide III Improves Mitochondrial Function and Protects Against Ulcerative Colitis by Activating AMPK/SIRT1/PGC-1α.

Authors:  Jieru Han; Wenhao Li; Guangyu Shi; Yunlei Huang; Xutao Sun; Na Sun; Deyou Jiang
Journal:  Mediators Inflamm       Date:  2022-04-08       Impact factor: 4.529

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.